acute myeloid leukemia (AML) | Aplastic Anemia & MDS International Foundation

acute myeloid leukemia (AML)

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Author(s): 
Justin Taylor, Xiaoli Mi, Alexander V Penson, Stella V Paffenholz, Kelsey Alvarez, Allison Sigler, Stephen S Chung, Raajit K Rampal, Jae H Park, Eytan M Stein, Martin S Tallman, Filiz Sen, Mithat Gönen, Omar Abdel-Wahab, Virgin M Klimek
Primary Author: 
Taylor, J
Journal Title: 
Lancet Hematology
Original Publication Date: 
Aug 2020

Background: The median overall survival of patients with high-risk

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Author(s): 
David A Sallman, Amy F McLemore, Amy L Aldrich, Rami S Komrokji, Kathy L McGraw, Abhishek Dhawan, Susan Geyer, Hsin-An Hou, Erika Adriana Eksioglu, Amy Sullivan, Sarah Warren, Kyle J MacBeth, Manja Meggendorfer, Torsten Haferlach
Primary Author: 
Sallman DA
Journal Title: 
Blood
Original Publication Date: 
Jul 2020

Somatic gene mutations are key determinants of outcome in patients with

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Author(s): 
Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A Gutman, Daniel A Pollyea
Primary Author: 
Kent, A
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2020

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

Author(s): 
Seongseok Yun, Susan M Geyer, Rami S Komrokji, Najla H Al Ali, Jinming Song, Mohammad Hussaini, Kendra L Sweet, Jeffrey E Lancet, Alan F List, Eric Padron, David A Sallman
Primary Author: 
Yun, S
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2020

The implementation of next-generation sequencing (NGS) has influenced diagnostic, prognostic, and therapeutic decisions in myeloid malignancies. However, the clinical relevance of serial molecular annotation in patients with myelodysplastic syndrome (MDS) undergoing active treatment is unknown. MDS or secondary

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML

Author(s): 
Feiteng Huang, Jie Sun, Wei Chen, Xin He, Yinghui Zhu, Haojie Dong, Hanying Wang, Zheng Li, Lei Zhang, Samer Khaled, Guido Marcucci, Jinwen Huang, Ling Li
Primary Author: 
Huang, F
Journal Title: 
Aging
Original Publication Date: 
Jul 2020

Aberrant DNA methylation often silences transcription of tumor-suppressor genes and is considered a hallmark of myeloid neoplasms. Similarly, histone deacetylation represses transcription of genes responsible for cell differentiation/death. A previous clinical study suggested potential pharmacodynamic antagonism between histone deacetylase inhibitors (HDACi) and DNA hypomethylating agents (HMA).

Thomas G. DeLoughery, MD, MACP, FAWM

DeLoughery, Thomas
Professor of Medicine
Oregon Health & Science University

Tom DeLoughery is a native Hoosier who graduated from Indiana State University in 1981 (one year after Larry Bird) and the Indiana University School of Medicine in 1985. He did his internship at the University of California, Irvine before traveling to Oregon where he finished his internal medicine residency and hematology/oncology fellowship.

Matt Kalaycio, MD

Kalaycio, Matt
Cleveland Clinic Taussig Cancer Center

Matt Kalaycio, MD, FACP, is the former Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. Dr. Kalaycio is also a Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology, Dr. Kalaycio's clinical interests are in leukemia and hematopoietic cell transplantation.

Ryan J. Mattison, MD

Mattison, Ryan
Associate Professor of Medicine
University of Wisconsin Health

Dr Mattison is an associate professor of medicine within the division of hematology/oncology at the University of Wisconsin School of Medicine and Public Health. He earned his medical degree at the University of Iowa Carver College of Medicine, Iowa City, IA. He completed his residency at University of North Carolina Hospitals, Chapel Hill, NC and his fellowship at the University of Chicago Hospitals, Chicago, IL. Dr. Mattison is board-certified in internal medicine, medical oncology and hematology.